Please enter a valid month/year e.g. 01/2015

Pick a date between March 2000 and March 2017

Showing 1 to 10 of 322
Title Reference number Published Last updated
Elotuzumab for previously treated multiple myeloma (terminated appraisal) Reference number:TA434 TA00434 Published:March 2017 20170301 Last updated:March 2017 20170322
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) Reference number:TA435 TA00435 Published:March 2017 20170301 Last updated:March 2017 20170322
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) Reference number:TA436 TA00436 Published:March 2017 20170301 Last updated:March 2017 20170322
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) Reference number:TA437 TA00437 Published:March 2017 20170301 Last updated:March 2017 20170322
Ustekinumab for treating active psoriatic arthritis Reference number:TA340 TA00340 Published:June 2015 20150601 Last updated:March 2017 20170303
Ustekinumab for the treatment of adults with moderate to severe psoriasis Reference number:TA180 TA00180 Published:September 2009 20090901 Last updated:March 2017 20170303
Everolimus for advanced renal cell carcinoma after previous treatment Reference number:TA432 TA00432 Published:February 2017 20170201 Last updated:February 2017 20170222
Apremilast for treating active psoriatic arthritis Reference number:TA433 TA00433 Published:February 2017 20170201 Last updated:February 2017 20170222
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation Reference number:TA429 TA00429 Published:January 2017 20170101 Last updated:January 2017 20170125
Sofosbuvir–velpatasvir for treating chronic hepatitis C Reference number:TA430 TA00430 Published:January 2017 20170101 Last updated:January 2017 20170125